Swiss Dental Startup vVardis Passes $1B Valuation, Weighs U.S. IPO

Swiss dental startup vVardis has surpassed a US$1 billion valuation and is now exploring an initial public offering in the United States, according to a report by Oral Health Group.

The company crossed the billion-dollar mark — the threshold that places it in the ranks of unicorns — before beginning work on a potential U.S. listing, according to the report. The precise valuation above US$1 billion, the identity of the banks involved and the intended listing venue were not disclosed.

vVardis is a Swiss startup operating in dental care. According to the Oral Health Group report, the company is weighing an American IPO as its next major financing step, a route that would take it from private markets to a U.S. exchange.

The move, if it proceeds, would add a European dental-technology name to a U.S. IPO pipeline. The report does not state a timeline for a possible filing, the size of any offering, or whether the company has mandated advisers.

A valuation above US$1 billion marks a significant milestone for a privately held company in the dental sector, where billion-dollar startups remain comparatively rare relative to software or biotechnology. It also sets the stage for the listing decision vVardis is now weighing.

The exploration of a U.S. IPO, rather than a European listing, signals where the company sees its future investor base and potentially its growth market. Any final decision on whether to proceed, and on what terms, would depend on market conditions at the time of a filing — details the report does not address.

For now, the confirmed facts are these: vVardis is Swiss, it operates in dental technology, its valuation has passed US$1 billion, and it is exploring a U.S. initial public offering, as reported by Oral Health Group. Whether that exploration turns into a filed registration statement, and at what valuation the company ultimately prices, will determine whether the dental startup becomes the sector's next public-market test case.